All therapiesEvidence snapshot 2026-09-13
Weight & glucose

Ribupatide

Activates both GLP-1 and GIP receptors. The injectable and oral formulations share these targets.

GLP-1s & metabolic therapies

At a glance

Selected evidence in this atlas
Studied use & population

Chinese adults with overweight or obesity without diabetes

Study context
Approval & development

China NDA accepted; global KaiNETIC phase 3 ongoing with doses to 10 mg.

Status sourceStatus & indications
Selected efficacy evidence

17.7% reported weight loss · 1.4% loss with placebo · 48 weeks

GEMINI-1 / HRS9531-301 · Phase 3 · sponsor · 6 mg once weekly · Regardless of stopping treatment

Evidence & limitations
Important safety context

6 mg: nausea 27.0%, vomiting 24.1%, diarrhea 35.5%; AE discontinuation 1.4%.

Safety context
Next milestone

A next milestone is not summarized for this therapy.

Milestone details

Study results apply to their own population, dose and analysis. They do not establish a ranking between therapies.

Evidence in the atlas

3 results

Each result belongs to its own study population, dose and analysis. Open a result for its chart, comparator, safety findings and limitations.

Weight loss

HRS9531 oral phase 2

11.4% reported weight loss · 2.1% loss with placebo · 26 weeks

50 mg once daily

Chinese adults with overweight or obesity without diabetes

Includes treatment discontinuation and other weight therapies. China phase 3 advancing; global phase 3 planned as early as the first half of 2027.

Safety context

50 mg: vomiting 7.5%, nausea 20%; no GI-related permanent discontinuations.

Limitations: Highest dose chosen; 25 mg had 11.9% loss. Efficacy-estimand 50 mg result 12.1% is separate.

Explore result Compare study Hengrui and Kailera present ribupatide clinical data at ADA 2026 · 2026-06-09
Weight loss

GEMINI-1 / HRS9531-301

17.7% reported weight loss · 1.4% loss with placebo · 48 weeks

6 mg once weekly

Chinese adults with overweight or obesity without diabetes

Includes premature treatment discontinuation and other weight-loss therapies. China NDA accepted; global KaiNETIC phase 3 ongoing with doses to 10 mg.

Safety context

6 mg: nausea 27.0%, vomiting 24.1%, diarrhea 35.5%; AE discontinuation 1.4%.

Limitations: China population; current global higher-dose phase 3 has no outcome yet.

Explore result Compare study Hengrui HRS9531 phase 3 GEMINI-1 detailed results at ObesityWeek 2025 · 2025-11-05
Glucose control

HRS9531 phase 2 core period

2.47 percentage-point HbA1c decrease · 0.3 pp decrease with Placebo · 20 weeks

4.5 mg weekly after escalation

Adults with type 2 diabetes

Hypothetical strategy using a repeated-measures model, excluding data after discontinuation, rescue therapy, or prohibited therapy.

Safety context

Most events were mild or moderate; diarrhea, reduced appetite, and nausea were common. No clinically significant or severe hypoglycemia was reported.

Safety source

Limitations: Core period shown. During the 32-week extension the placebo group switched to HRS9531, so it is no longer a placebo-only comparison. Highest dose shown; 3 mg had a numerically larger HbA1c decrease.

Explore result Compare study HRS9531 diabetes results, ADA 2025 slide 6 · 2025-06-20

Biology & identity

Status in this atlas: China NDA accepted; global KaiNETIC phase 3 ongoing with doses to 10 mg. Status source

Hormone activity

GLP-1Activates receptorsGIPActivates receptors

Activates both GLP-1 and GIP receptors. The injectable and oral formulations share these targets.

What do these hormones do? GLP-1 · GIP

No approved trade name verified. HRS9531, KAI-9531 and KAI-9531-T are development codes; injectable and oral products remain distinct formulations.

Hengrui Pharma · Originator and Greater-China developer.; Kailera Therapeutics · Exclusive development and commercialization licensee outside China, Hong Kong, Macau and Taiwan.

Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.

The molecule

Activates both GLP-1 and GIP receptors. The injectable and oral formulations share these targets.
Structure not yet verified

Structure not verified

Activates both GLP-1 and GIP receptors. The injectable and oral formulations share these targets.

Shown: Peptide drug

An exact-drug structure was not verified in this review. The named PubChem lookup did not return a compound record; no related hormone or analogue is substituted.

Ribupatide

Development timeline

Next milestone

A next milestone is not summarized for this therapy. This does not mean development has ended.

Development history3 selected milestones

Ribupatide · compound history across indications

Selected milestones only. Earlier studies may be missing; the first listed date should not be interpreted as the start of development.

  1. Kailera acquires regional rights

    Hengrui licensed the metabolic portfolio to Kailera for worldwide development and commercialization outside Greater China.

    Source

  2. Injectable GEMINI-1 results reported

    Hengrui presented the 48-week Chinese phase 3 obesity results for weekly injection.

    Source

  3. Oral phase 2 data presented

    Detailed 26-week results for daily oral ribupatide were presented at ADA, including treatment-policy results.

    Source

Selected sources checked Sep 13, 2026. This is not an exhaustive history.